Skip to Main Content
Contribute Try STAT+ Today

Every day, countless people across America order prescription drugs from pharmacies in other countries as they hunt for something increasingly elusive — affordable medications.

But there’s a problem. Under most circumstances, importing medicines is illegal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I appreciate Mr. Levitt’s gracious apology and reply. Would that more of our public discourse were characterized by courtesy of this kind.

    • Dear Ron and Gabe,

      This is a belated thanks for sharing your thoughts on a difficult topic. I believe you both make valid points that are worth considering if the matter is to be pursued. I’ve said my piece for now, so will leave it at that.

      All best,
      ed at pharmalot

  • A final point: in the end, the price of a drug, or of any healthcare service, should bear a relationship to its value. The cost of all healthcare in the US is far higher than in other countries–this includes the costs of office visits, diagnostics, devices, surgeries, hospitalizations, etc., and drugs are no more costly relative to, say, Canada or the EU, than are these other healthcare goods and services. Our system defaults to paying for volume rather than for outcomes. We should be striving to shift our entire system to one that pays for value and better health outcomes, rather than by the piece.

Comments are closed.